Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclosporine for severe ulcerative colitis.

Co Q D Pham1, Carly B Efros, Rosemary R Berardi

  • 1University of Michigan College of Pharmacy, Ann Arbor, MI 48109-1065, USA.

The Annals of Pharmacotherapy
|December 22, 2005
PubMed
Summary

Intravenous cyclosporine effectively treats severe ulcerative colitis refractory to steroids. Initiate therapy with a lower dose to minimize side effects and use it as a bridge to other maintenance medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The value of branded proton pump inhibitors: formulary considerations.

P & T : a peer-reviewed journal for formulary management·2011
Same author

Advances in gastrointestinal pharmacotherapy--who would have thought?

The Annals of pharmacotherapy·2007
Same author

The art of assessing metronidazole toxicity.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2006
Same author

Urinary tract infections in extended care facilities: preventive management strategies.

The Consultant pharmacist : the journal of the American Society of Consultant Pharmacists·2006
Same author

Acid suppressive therapy use on an inpatient internal medicine service.

The Annals of pharmacotherapy·2006
Same author

Safety and tolerability of tegaserod in irritable bowel syndrome management.

Journal of the American Pharmacists Association : JAPhA·2004

Area of Science:

  • Gastroenterology
  • Immunosuppression Therapy

Background:

  • Severe ulcerative colitis (UC) poses significant treatment challenges, often requiring advanced immunosuppressive strategies.
  • Corticosteroid-refractory UC necessitates exploring alternative therapies to induce remission and prevent colectomy.

Purpose of the Study:

  • To evaluate the efficacy and safety of cyclosporine in treating patients with severe ulcerative colitis.
  • To synthesize evidence from randomized controlled trials and other studies on cyclosporine for UC.

Main Methods:

  • Comprehensive literature search of MEDLINE, EMBASE, Cochrane Database, and ISI Web of Knowledge (1966-2005).
  • Inclusion of human adult studies published in English, focusing on cyclosporine (CsA) for ulcerative colitis (UC).
  • Review of 4 randomized controlled trials and numerous open-label/retrospective studies.

Main Results:

  • Four controlled trials demonstrated initial clinical response with intravenous cyclosporine (4 mg/kg/day) in severe UC.
  • Cyclosporine showed efficacy as monotherapy or adjunct to corticosteroids in inducing remission.
  • High-dose cyclosporine offered no additional benefit over low-dose, with lower doses potentially improving safety profiles.

Conclusions:

  • Intravenous cyclosporine is supported by evidence for steroid-refractory severe UC.
  • Initiate cyclosporine therapy at 2 mg/kg/day, monitoring blood levels (150-250 ng/mL) and adjusting doses.
  • Cyclosporine should serve as a short-term "bridge" to azathioprine or 6-mercaptopurine maintenance therapy; long-term monotherapy data are insufficient.

Related Experiment Videos